Brown AND Burk UK Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Brown AND Burk UK Limited Pharmaceutical Import Records from India — 6 Products, $16.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brown AND Burk UK Limited — Pharmaceutical Importer Profile (2026) | 6 Products, $16.5M Trade | TransData Nexus

Brown AND Burk UK Limited

Pharmaceutical Importer · United Kingdom · CNS & Psychiatric Focus · $16.5M Total Trade · DGFT Verified

Brown AND Burk UK Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $16.5M across 6 products in 5 therapeutic categories. Based on 377 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Brown AND Burk UK Limited sources from 2 verified Indian suppliers, with Micro Labs Limited accounting for 99.7% of imports.

Brown AND Burk UK Limited — Import Portfolio & Supplier Network

Brown AND Burk UK Limited import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Brown AND Burk UK Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$37.0M	1,549	99.7%
Valugen Pharma Private Limited	$100.0K	4	0.3%

Brown AND Burk UK Limited sources from 2 verified Indian suppliers across 1,186 distinct formulations. The sourcing is highly concentrated — Micro Labs Limited accounts for 99.7% of total imports, indicating a strategic single-source relationship.

What Formulations Does Brown AND Burk UK Limited Import?

Formulation	Value	Ships
Flucloxacillin 500MG capsules, hard (BP)	$700.0K	22
Ramipril 2.5 MG capsules (in bb livery)	$521.9K	15
Flecainide acetate 100 MG tablets (in	$400.0K	8
Gabapentin brown & burk 300 MG capsules	$350.0K	7
Co-amoxiclav 500MG/125MG Film-Coated TAB	$331.7K	8
Carbocisteine capsules 375 MG, hard	$250.0K	5
Gabapentin brown & burk 600MG film -	$211.5K	5
Flucloxacillin 500MG capsules, hard (BP)	$200.0K	4
Flucloxacillin 500MG capsules hard (BP	$200.0K	4
Flecainide acetate 50MG tablets in bb	$200.0K	4
Phenoxymethylpenicillin 250MG	$170.0K	7
Carbocisteine capsules 375 MG hard(8x15s	$167.2K	4
Ramipril 5MG capsules in bb livery	$150.0K	5
Gabapentin brown burk 300 MG capsules	$150.0K	3
Flecainide acetate 100 MG tablets in	$150.0K	3

Brown AND Burk UK Limited imports 1,186 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gabapentin	CNS & Psychiatric	$6.5M	130	0.8%	15
2	Ramipril	Cardiovascular	$4.0M	125	4.4%	4
3	Flucloxacillin	Advanced Antibiotics	$3.4M	68	8.8%	3
4	Clarithromycin	Antibiotics	$1.6M	32	1.6%	7
5	Lisinopril	Cardiovascular	$852.4K	19	1.4%	5
6	Vati	Ayurvedic & Herbal Products	$150.0K	3	0.6%	16

Brown AND Burk UK Limited imports 6 pharmaceutical products across 5 categories into United Kingdom totaling $16.5M.

Brown AND Burk UK Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Brown & Burk UK Limited is a privately held pharmaceutical company based in the United Kingdom, specializing in the manufacturing, marketing, and distribution of generic medicinal products. Established on 2 October 2000, the company is headquartered at Micro House, 5 Marryat Close, Hounslow, Middlesex, TW4 5DQ. (find-and-update.company-information.service.gov.uk) The company's mission is to provide high-quality, EU GMP-compliant generic pharmaceuticals, ensuring a reliable and controlled supply chain to meet the healthcare needs of communities.

Brown & Burk UK Limited operates as a fully integrated generic pharmaceutical supplier in the UK, focusing on delivering medicines efficiently from manufacturers to patients. The company emphasizes a "right-first-time, on time, every time" approach to deliveries, aiming to reduce lead times and implement just-in-time (JIT) supply concepts. This commitment to quality and efficiency has positioned Brown & Burk UK Limited as a significant player in the UK's pharmaceutical distribution landscape.

2Distribution Network

The company's distribution network is strategically designed to ensure timely and efficient delivery of pharmaceutical products across the United Kingdom. While specific warehouse locations are not publicly disclosed, Brown & Burk UK Limited's operations are centralized at their headquarters in Hounslow, Middlesex. (find-and-update.company-information.service.gov.uk) The company emphasizes a reliable and controlled supply chain, aiming to reduce lead times and implement just-in-time (JIT) supply concepts. This approach suggests a well-organized logistics capability, enabling the company to serve a broad geographic area within the UK effectively.

3Industry Role

Brown & Burk UK Limited plays a pivotal role in the United Kingdom's pharmaceutical supply chain as a generic pharmaceutical manufacturer and distributor. By focusing on the production and distribution of generic medicines, the company contributes to enhancing the accessibility and affordability of healthcare in the UK. Their commitment to quality and efficiency has established them as a significant player in the UK's pharmaceutical distribution landscape.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Brown AND Burk UK Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Brown & Burk UK Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of their pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $16.5 million USD from India, encompassing 377 shipments and 1,186 unique formulations across six products and five therapeutic categories. The top five imported products include Gabapentin ($6.5 million, 0.8% share), Ramipril ($4.0 million, 4.4% share), Flucloxacillin ($3.4 million, 8.8% share), Clarithromycin ($1.6 million, 1.6% share), and Lisinopril ($852,000, 1.4% share). Notably, the top five products account for 99.1% of the total import value, indicating a highly concentrated product portfolio.

This sourcing concentration suggests a strategic choice by Brown & Burk UK Limited to focus on a select range of high-demand generic pharmaceuticals. The stability of their relationship with Indian suppliers, particularly MICRO LABS LIMITED, which accounts for 99.7% of the shipments, is crucial. The company's reliance on a single supplier for the majority of their imports may pose risks related to supply chain disruptions, pricing fluctuations, and geopolitical factors affecting trade relations.

2Supply Chain Resilience

The resilience of Brown & Burk UK Limited's supply chain is closely tied to their sourcing strategy from India. The company's dependence on a single supplier, MICRO LABS LIMITED, for 99.7% of their pharmaceutical imports, indicates a concentrated supply chain. While this concentration may offer benefits such as streamlined operations and potentially favorable pricing, it also exposes the company to risks associated with supply chain disruptions, regulatory changes, and geopolitical tensions affecting trade relations between the UK and India.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the safety, efficacy, and quality of medicines and medical devices. The MHRA operates under the framework of the Human Medicines Regulations 2012, which transposes European Union directives into UK law. This legislation outlines the requirements for the manufacture, import, distribution, and marketing of medicinal products within the UK.

For Indian pharmaceutical companies exporting to the UK, obtaining a Marketing Authorization (MA) from the MHRA is essential. The MA process involves submitting comprehensive data on the product's quality, safety, and efficacy, along with manufacturing details. Additionally, compliance with Good Manufacturing Practice (GMP) standards, as recognized by the MHRA, is mandatory to ensure product quality and patient safety.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the UK are governed by the MHRA. Indian exporters must ensure that their products have obtained a valid Marketing Authorization (MA) from the MHRA before importation. The MA process requires the submission of detailed documentation, including clinical trial data, manufacturing processes, and quality control measures.

Compliance with Good Manufacturing Practice (GMP) is a critical requirement for pharmaceutical imports. The MHRA recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian manufacturers seeking to export to the UK must ensure that their facilities are certified by one of these recognized bodies to meet the MHRA's standards.

Brown AND Burk UK Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Brown & Burk UK Limited's product strategy focuses on high-demand generic pharmaceuticals across therapeutic areas such as Central Nervous System (CNS) & Psychiatric, Cardiovascular, and Advanced Antibiotics. Between 2022 and 2026, the company imported products like Gabapentin, Ramipril, Flucloxacillin, Clarithromycin, and Lisinopril, with the top three categories accounting for 39.5%, 29.3%, and 20.6% of the total import value, respectively.

This strategic focus aligns with market demand for cost-effective treatments in these therapeutic areas, addressing prevalent health conditions in the UK. By concentrating on these categories, Brown & Burk UK Limited aims to meet the needs of healthcare providers and patients, ensuring the availability of essential medicines.

2Sourcing Profile

Brown & Burk UK Limited's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a significant emphasis on generic drugs. The company's portfolio includes a diverse range of formulations, with 1,186 unique formulations imported across six products and five therapeutic categories between 2022 and 2026. This approach allows the company to offer a comprehensive product range while maintaining a focus on high-demand generic

TransData Nexus Research · DGFT trade data analysis

Frequently Asked Questions — Brown AND Burk UK Limited

What products does Brown AND Burk UK Limited import from India?

Brown AND Burk UK Limited imports 6 pharmaceutical products across 5 categories. Top imports: Gabapentin ($6.5M), Ramipril ($4.0M), Flucloxacillin ($3.4M), Clarithromycin ($1.6M), Lisinopril ($852.4K).

Who supplies pharmaceuticals to Brown AND Burk UK Limited from India?

Brown AND Burk UK Limited sources from 2 verified Indian suppliers. The primary supplier is Micro Labs Limited (99.7% of imports, $37.0M).

What is Brown AND Burk UK Limited's total pharmaceutical import value?

Brown AND Burk UK Limited's total pharmaceutical import value from India is $16.5M, based on 377 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Brown AND Burk UK Limited focus on?

Brown AND Burk UK Limited imports across 5 categories. The largest: CNS & Psychiatric (39.5%), Cardiovascular (29.3%), Advanced Antibiotics (20.6%).

Get Full Brown AND Burk UK Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.